SmurfVA's Random Picks

[Ned Serious]

Bio Sentiment Watch: FOLD $2.16 - Yesterday Good news. Pops 30% on open - Holds there around 15 mins, then fades all day. Down 2% Today in early action.

I'm just continuing to watch - to get a feel of how the Bios are reacting now in this - "Does the market still like Bios?" times.

----------------------------------

link: http://www.valuewalk.com/2014/04/amicus-therapeutics-inc-fold-soars-on-positive-results/

According to Amicus Therapeutics, Inc. (NASDAQ:FOLD), patients who switched from placebo to migalastat after month 6 demonstrated a statistically significant reduction in kidney interstitial capillary GL-3 (p=0.013) on month 12. Those who remained on migalastat for 12 months experienced a durable reduction kidney interstitial capillary GL-3.

The biopharmaceutical company said reduction in disease substrate was observed in plasma lyso-Gb3 in patients who switched from placebo to migalstat (p< 0.0001).

Amicus Therapeutics, Inc. (NASDAQ:FOLD) said kidney function (estimated glomerular filtration rate (eGFR), iohexol mGFR) remained stable over 18-24 months and migalastat was well tolerated by patients and was generally safe. According to the company, 85% or 35 of the 41 subjects with GLP HEK amenable mutations who completed the Study 011 remained in the voluntary extension study.